CB Therapeutics Announces Closing of the Latest Round of Equity Funding for Scaling Up Biosynthesis Research and Production

CB Therapeutics, an innovative biotechnology company focusing on research and production of wellness compounds, announced the closing of the first round of equity funding for its research projects. The company raised $7.5 M to establish world-class research facilities in the Southern California region and assemble an impressive scientific team.

We are excited to announce this milestone, said Sher Ali Butt, CEO and co-founder of CB Therapeutics. With the establishment of our labs in the Southern California area, we are poised to accelerate our research efforts and address the ever-growing demand for our services from entities in the U.S. and abroad. We are appreciative and encouraged from the support weve received from our partners and we are looking forward to implementing the next steps of our growth strategy.

About CB Therapeutics

CB Therapeutics utilizes sustainable microorganisms and its proprietary biotechnology platform to produce therapeutic compounds found in nature. Through biosynthesis, CB Therapeutics has produced various rare compounds that have not been previously available due to the difficulty producing them and the cost inefficiencies in extracting them from nature.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Sher Ali Butt
[email protected]